TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03957733
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long course CRT is followed by 4 cycles of combination chemotherapy of modified FOLFOX6 or 3 cycles of XELOX (capecitabine and oxaliplatin) and then surgery
Study: NCT00731016
Drug: Zoledronic acid, pravastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin : 10 mg daily~Zoledronic acid : slow (30 mn) intravenous injections, diluted into 50 ml of saline solution following this schedule :~* injection 1, S1: 0.0125 mg/kg of zoledronic acid~* injection 2, S6: 0.025 mg/kg of zoledronic acid~* injection 3, S12 and following, trimestrial basis, 0.05 mg/kg of zoledronic acid
Study: NCT04466176
Drug: Test Product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT04466176
Drug: Reference Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT04527471
Drug: Placebo pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo delivered twice daily via pMDI
Study: NCT02344862
Drug: FYU-981 High dose, (Oral daily dosing for 8 weeks)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
Study: NCT02344862
Drug: FYU-981 Middle dose, (Oral daily dosing for 8 weeks)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
Study: NCT02344862
Drug: FYU-981 Low dose, (Oral daily dosing for 8 weeks)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
Study: NCT02344862
Drug: Placebo, (Oral daily dosing for 8 weeks)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the placebo arm receive placebo.
Study: NCT00658008
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, oral, placebo bid, 8 weeks with 2 week taper
Study: NCT03972982
Drug: Simplified intensive insulin therapy regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-term continuous subcutaneous insulin infusion to maitain near normoglycemica for 1 week, thereafter basal insulin and metformin were subsequently used. Wearable devices and smart apps will be used for lifestyle modification.
Study: NCT01266174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match eltoprazine
Study: NCT02971410
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03277690
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the double-blind Withdrawal Phase, patients will receive placebo tablets.~During the double-blind Restoration Phase, patients will receive placebo plus levoketoconazole.
Study: NCT04562467
Drug: Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]
Normalized name: ICOSAPENT ETHYL 1000 mg ORAL CAPSULE [Vascepa]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 1g capsules BID as per REDUCE-IT
Study: NCT00416546
Drug: AEB071
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04110678
Drug: NeuroEPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeuroEPO \[CIMAB S.A, Havana, Cuba\]
Study: NCT01719978
Drug: 3.6mL 2% Mepivacaine with 1:100,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic with vasoconstrictor
Study: NCT01719978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mL 0.9% saline administration concomitant to the local anesthetic
Study: NCT01117948
Drug: Lornoxicam
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
Study: NCT01117948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
Study: NCT02592122
Drug: No drugs
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03893175
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
Study: NCT03893175
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
Study: NCT03893175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: By mouth
Study: NCT00493532
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg iv every 3 months
Study: NCT04047576
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects. For active comparator group, if a patient is assessed as treatment failure (TF), the patient should be withdrawn from the study and receive rescue treatment.
Study: NCT04124653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administration of placebo
Study: NCT00294801
Drug: flex-a-new (food supplement)
Normalized name: Ed Flex
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02380001
Drug: Dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: White round pill containing 25mg of Dexketoprofen will be administered either prior/after to third molar surgery.
Study: NCT00295854
Drug: MN-001 BID
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients received 500 mg MN-001 bid
Study: NCT00295854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients received placebo
Study: NCT03800173
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo IV infusion
Study: NCT00936611
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04893148
Drug: IGlarLixi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changing to iGlarLixi from insulin glargine
Study: NCT01074372
Drug: REGN727
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cohorts (dose 1, 2, 3, 4)
Study: NCT01501695
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: mimetic granule: same with 5LGr mimetic tablet: same with tiapride
Study: NCT02259842
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03051256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
Study: NCT01074372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cohorts (dose 1, 2, 3, 4)
Study: NCT04272359
Drug: Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substitution of sulfonylureas with other classes of new hypoglycaemic drugs. In every group, it will be evaluated:~* efficacy in terms of glycometabolic compensation (glycemia, HbA1c, lipid profile);~* effects on BMI, blood pressure monitoring and hypoglycemic risk;~* changes in renal function and microalbuminuria;~* tolerability and side effects of the new therapeutic regimes;~* therapeutic adherence;~* post-prandial glycemic excursion, determined by a 6-point glycemic diary (pre- and 2h post-prandial glucose values) to be performed at home in the week before the scheduled follow-up visit;~* effects on chronic complications of diabetes and cardiovascular safety.
Study: NCT04295772
Drug: DOR/ISL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.
Study: NCT02608203
Drug: [68Ga]-DOTANOC PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01103037
Drug: QAV680
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAV680 500 mg (5 x 100 mg capsules) four times per day
Study: NCT01103037
Drug: QAV680 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to QAV680 5 capsules four times per day
Study: NCT02730689
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00968383
Drug: Platelet inhibitors
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive platelet inhibitors.
Study: NCT00968383
Drug: ACE inhibitors and/or ARB and/or AA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ACE inhibitors and/or ARB and/or AA
Study: NCT01604187
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ten minutes before the procedure fentanyl sublingual tablet (Abstral ® 100 µg, ProStrakan) will be given to the patient.
Study: NCT01604187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
Study: NCT00412997
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00673361
Drug: Concurrent decrescendo biochemotherapy regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Temozolomide: 200mg/m\^2, daily, PO, days 1-4~* Vinblastine: 1.5mg/m\^2, daily, IV, days 1-4~* Cisplatin: 20mg/m\^2, daily IV, days 1-4~* IL (interleukin)-2: - 18 milli-International unit (MIU)/m\^2, IVCI (intravenous continual infusion), day 1~* 9 MIU/m\^2, IVCI, day 2~* 4.5 MIU/m\^2, IVCI, days 3 \& 4~* Interferon (IFN) alpha: 5 MIU/m\^2, daily, SC (subcutaneously), days 1-5~* 5-day inpatient regimen, to be repeated every 21 days
Study: NCT02770170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00829413
Drug: SonoVue®
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue (2.4 mL)
Study: NCT02670434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 12 weeks
Study: NCT03691935
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector Spinae Block with saline infusion with standard of care analgesics for for perioperative pain control
Study: NCT03382106
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo manufactured to look like Sildenafil 20 MG
Study: NCT00535522
Drug: TAK-285 Recommended Phase 2 Dosing Cohort
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Expanded cohort with dose and regimen dependent upon the safety profile of the maximally tolerated dose and schedule determined in the dose escalation phase of the study.
Study: NCT03522922
Drug: Topical Vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: The used vitamin C product was in the form of 17% concentration of L- Ascorbic Acid serum that was encapsulated in gelatinous capsules each contain 1 mg of the serum. The patient instructed to open one capsule and apply its serum content on the treatment area daily at night. This capsule form for topical application help to insure stability of the product and also insure use of equal dose in each application
Study: NCT01075763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The inactive substance (placebo) looks the same as Interferon beta-1a (Rebif®), and is given the same way
Study: NCT00122096
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03182179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is taken orally BD
Study: NCT03181893
Drug: Placebo Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid
Study: NCT00957983
Drug: BGC20-1531
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration followed by Prostaglandin E2 infusion
Study: NCT03439787
Drug: Bupivacaine-EPINEPHrine 0.5%-1:200,000 Injectable Solution
Normalized name: bupivacaine-epinephrine 0.5%-1:200,000 injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml
Study: NCT02656914
Drug: Irlanda-2-Association
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 10 mL every 12 hours (2x/day), oral route.
Study: NCT02656914
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 10 mL every 12 hours (2x/day), oral route.
Study: NCT01219673
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg by mouth twice a day.
Study: NCT02009306
Drug: Standard subcutaneous medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous as needed medication will include:~* Opioids for pain or dyspnoea~  * Diamorphine~ * Oxycodone~ * Fentanyl~* Benzodiazepine and / or anti-psychotic for agitation~  * Midazolam~ * Levomepromazine~ * Haloperidol Anti-emetic for nausea~* Cyclizine~* Metoclopramide~* Haloperidol~* Levomepromazine~* Anti-secretory drug for respiratory secretions~* Glycopyrronium~* Hyoscine butylbromide~* Hyoscine hydrobromide
Study: NCT01393223
Drug: LP-08 80mg
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of 80mg LP08
Study: NCT01393223
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of normal saline
Study: NCT01393223
Drug: LP-08 20mg
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of 20mg LP08
Study: NCT00580853
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02231190
Drug: GSK1278863
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1278863 will be supplied as oral tablet of strength 100mg, 5mg(5mg if a low dose is elected for subjects enrolled after interim analysis) to be administered with 240 mL of water after end of eccentric exercise
Study: NCT02231190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1278863 matching placebo will be supplied as oral tablets for administration with 240 mL of water after end of eccentric exercise
Study: NCT02079948
Drug: Methotrexate + Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in the methotrexate + folic acid condition will have a~* Blood draw at each monthly visit~* Cognitive performance testing to assess memory performance~* Physical function testing to assess walking speed and measure muscle endurance~* Pain assessment testing to assess the presence and location of daily pain~* Self-reported function and quality of life to measure disability and mobility limitations, and~* Depression assessment testing to assess participants' level of depression.
Study: NCT02079948
Drug: Placebo + Folic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the placebo + folic acid condition will have a~* Blood draw at each monthly visit~* Cognitive performance testing to assess memory performance~* Physical function testing to assess walking speed and measure muscle endurance~* Pain assessment testing to assess the presence and location of daily pain~* Self-reported function and quality of life to measure disability and mobility limitations, and~* Depression assessment testing to assess participants' level of depression
Study: NCT01127581
Drug: MVI 200
Normalized name: alpha-tocopherol acetate / ascorbic acid / biotin / dexpanthenol / ergocalciferol / folic acid / niacinamide / pyridoxine hydrochloride / riboflavin / thiamine hydrochloride / vitamin A / vitamin B12 / vitamin K1 Injectable Solution [MVI Pediatric]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Study: NCT01127581
Drug: Dinoprostone Vaginal Insert (DVI)
Normalized name: dinoprostone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Study: NCT01686828
Drug: Testosterone 1.62% gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal Testosterone Gel (either 1.25g or 5g/d) for 4 weeks
Study: NCT01686828
Drug: Placebo gel (for Testosterone 1.62% gel)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo gel manufactured to mimic Testosterone 1.62% gel
Study: NCT00261729
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules
Study: NCT03605706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive placebo of SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
Study: NCT01197664
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03179618
Drug: Anti-Platelet Drugs
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Including aspirin and clopidogrel, etc.
Study: NCT03179618
Drug: Lipid Regulating Drugs
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainly including statins
Study: NCT03179618
Drug: Coronary Vasodilator
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainly including nitrates
Study: NCT03179618
Drug: Xuefu Zhuyu Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
Study: NCT03216187
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules identical to pregabalin but without active drug
Study: NCT02916979
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate:~Related donors: 5 mg/m2 on days 1, 3 and 6 Unrelated donors: 5 mg/m2 on days 1, 3, 6 and 11
Study: NCT01811277
Drug: SOX sequential S-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-6 cycles SOX followed by S-1 monotherapy until disease progression~S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
Study: NCT01725477
Drug: methylen blue &normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Washing after dye injection
Study: NCT00626925
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (12 weeks during which the dosage of study medication is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
Study: NCT01381484
Drug: 10% Argireline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Argireline (La jolie gel®, Pacific health care, Thailand) were instructed to apply the gel over the face and periorbital area twice daily for a period of 3 months.
Study: NCT03378661
Drug: E1224 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: E1224 matched placebo capsules
Study: NCT05433428
Drug: Preservative Free
Normalized name: preservative free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative free eye drops
Study: NCT01871142
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL
Study: NCT00942448
Drug: Diclofenac HPBCD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 single injection at day of dental surgical extraction
Study: NCT01072383
Drug: placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of the end formulation buffer of BT061 without active ingredient, either subcutaneous or intravenous
Study: NCT00002895
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03281369
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin: 100 mg/m\^2 IV over 2 hours on Days 1 and 15 of every 28-day cycle.
Study: NCT01829477
Drug: TAK-875 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-875 placebo-matching tablets
Study: NCT01953497
Drug: URC102
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00478946
Drug: (FOLPI) Picoplatin with 5-FU and Leucovorin
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
Study: NCT00478946
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m. Leucovorin (400 mg/m2 in D5W). Oxaliplatin and leucovorin Leucovorin + oxaliplatin 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
Study: NCT01215942
Drug: LY2127399
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Subcutaneously
Study: NCT00198081
Drug: COX-2 Inhibitor 6-8 weeks prior to surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg BID 6-8 weeks prior to surgery
Study: NCT00198081
Drug: COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg BID for 6 months prior to follow-up EUS or ERCP
Study: NCT03896217
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40mg for first 4 weeks and 80mg (if tolerated) thereafter up to 17 weeks
Study: NCT01890746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose given was matching 300 mg Eltrombopag if platelet counts were \<100 Gi/L. Placebo continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage placebo matching 100 mg Eltrombopag orally once daily was used and after 7 days, the placebo matching 150 mg Eltrombopag was given if platelet counts were \<100 Gi/L.